Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Official Title: “Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis”

The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

Intervention(s) in this Clinical Trial

• Drug: Anastrozole

Arms, Groups and Cohorts in this Clinical Trial

• : 1
  • all patients treated with Anastrozole

Primary Measures

• evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions
  • Time Frame: 12 months
    Safety Issue?: No

Secondary Measures

• description of population treated with anastrozole
  • Time Frame: 12 months
    Safety Issue?: No
• further information about the change of specific laboratory parameters
  • Time Frame: 12 months
    Safety Issue?: No

Inclusion Criteria:

• Postmenopausal women with early hormone receptor positive breast cancer/no metastasis

Exclusion Criteria:

• None

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: AstraZeneca Industry

Overall Clinical Trial Officials and Contacts

H Brasch Study Director AstraZeneca Germany  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00638391

Study ID Number: Ax-003

ClinicalTrials.gov Identifier: NCT00638391

Health Authority: Germany: Federal Institute for Drugs and Medical Devices